These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12749519)

  • 21. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
    Pellissier JM; Straus WL; Watson DJ; Kong SX; Harper SE
    Clin Ther; 2001 Jul; 23(7):1061-79. PubMed ID: 11519771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
    Schaefer M; DeLattre M; Gao X; Stephens J; Botteman M; Morreale A
    Curr Med Res Opin; 2005 Jan; 21(1):47-60. PubMed ID: 15881475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
    Malmstrom K; Fricke JR; Kotey P; Kress B; Morrison B
    Clin Ther; 2002 Oct; 24(10):1549-60. PubMed ID: 12462285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
    Weideman RA; Kelly KC; Kelley CL; Cryer B
    Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of rofecoxib and celecoxib with warfarin.
    Schaefer MG; Plowman BK; Morreale AP; Egan M
    Am J Health Syst Pharm; 2003 Jul; 60(13):1319-23. PubMed ID: 12901032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A; Goldkind L; Bonnel R; Beitz J
    Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cox-2 inhibitors.
    Strassels S
    J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
    Bouée S; Charlemagne A; Fagnani F; Le Jeunne P; Sermet C; Naudin F; Lancry PJ
    Joint Bone Spine; 2004 May; 71(3):214-20. PubMed ID: 15182793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery.
    Watcha MF; Issioui T; Klein KW; White PF
    Anesth Analg; 2003 Apr; 96(4):987-994. PubMed ID: 12651647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cyclooxygenase-2 inhibitors on blood pressure.
    Johnson DL; Hisel TM; Phillips BB
    Ann Pharmacother; 2003 Mar; 37(3):442-6. PubMed ID: 12639178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.